$79.17
Value $2.0B
IOSP and LIN stock compared: price, dividend, valuation and results, from SEC filings.
$79.17
Value $2.0B
$523.46
Value $243B
Innospec (IOSP) has a market value of $2.0B and Linde (LIN) $243B. Over the last year, with dividends, IOSP moved +9.5% and LIN +25.3%. The P/E is 14.0 for IOSP and 34.6 for LIN. Dividend yield: IOSP 2.26%, LIN 1.20%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
IOSP$2.0B
LIN$243B
LIN is 124 times IOSP
Revenue, 12 months
IOSP$1.9B
LIN$36.2B
LIN is 19 times IOSP
Net income, 12 months
IOSP$140M
LIN$7.0B
LIN is 50 times IOSP
Operating margin
IOSP8.8%
LIN25.3%
16.5 points apart
ROIC
IOSP10.0%
LIN11.1%
1.1 points apart
P/E
IOSP14.0
LIN34.6
LIN is 2.5 times IOSP
Dividend yield
IOSP2.3%
LIN1.2%
1.1 points apart
5-year return
IOSP-7.6%
LIN+67.7%
75.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
IOSP-7.6%
LIN+67.7%
| Period | IOSPWith dividends | LINWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +9.5%Price +6.9% | +25.3%Price +23.6% |
| 3 years since November 16, 2023 | -23.3%-8.4% a yearPrice -27.2% | +33.2%+10.0% a yearPrice +28.2% |
| 5 years since November 15, 2021 | -7.6%-1.6% a yearPrice -14.0% | +67.7%+10.9% a yearPrice +56.7% |
| 10 years since November 16, 2016 | +46.7%+3.9% a yearPrice +28.4% | +427.2%+18.1% a yearPrice +346.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
IOSPInnospecLINLinde
| Price | $79.17 | $523.46 |
|---|---|---|
| Market value | $2.0B | $243B |
| Enterprise value (EV) | $1.7B | $264B |
| P/E | 14.0 | 34.6 |
| P/E, 5-year median | 22.2 | 32.6 |
| P/B | 1.4 | 6.2 |
| EV/EBIT | 10.4 | 28.8 |
| Free cash flow yield | 2.3% | 2.1% |
| Revenue, 12 months | $1.9B | $36.2B |
|---|---|---|
| Net income, 12 months | $140M | $7.0B |
| Free cash flow, 12 months | $46M | $5.1B |
| Earnings per share, 12 months | $5.67 | $15.06 |
| Revenue growth, year on year | -3.7% | 3.0% |
| Revenue growth a year, past | +8.3%over 5 years | +4.5%over 5 years |
| EPS growth a year, past | +32.1%over 5 years | +25.4%over 5 years |
| Gross margin | 27.7% | 47.9% |
|---|---|---|
| Operating margin | 8.8% | 25.3% |
| Net margin | 7.5% | 19.3% |
| ROIC | 10.0% | 11.1% |
| ROE | 10.5% | 18.1% |
| Cash | $252M | $3.9B |
|---|---|---|
| Total debt | $47M | $25.2B |
| Net debt / EBITDA | -1.2 | 1.7 |
| Interest cover | – | 35.5× |
| Dividend yield | 2.3% | 1.2% |
|---|---|---|
| Dividend per share, 12 months | $1.79 | $6.30 |
| Dividend growth a year, past | +10.5%over 5 years | +9.3%over 5 years |
| Buyback yield | 1.2% | 1.9% |
| Shareholder yield | 3.5% | 3.1% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Linde ($243B) is about 123.7 times Innospec ($2.0B), at today's prices.
Since November 16, 2016, IOSP's price moved +28.4% and LIN's +346.8%. With dividends: IOSP +46.7% (+3.9% a year), LIN +427.2% (+18.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.26% for Innospec and 1.20% for Linde. Over the last twelve months they paid $1.79 and $6.30 per share.
At today's price, the P/E is 14.0 for IOSP and 34.6 for LIN. The median of the last five years was 22.2 and 32.6, which shows where each stands against its own past.
Over the last twelve months, the net margin was 7.5% for Innospec and 19.3% for Linde, and the operating margin 8.8% and 25.3%. Revenue was $1.9B and $36.2B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.